Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Read the highlights for the 2026 World Alzheimer's Month campaign, from ADI member activities to key events and achievements from the wider community of advocates united under the theme of ‘The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters’.
ADI announces our new CEO, joining on 1 October 2026
In this guest article, ADI Board Member and dementia advocate, Bill Yeates, shares his post diagnosis journey, discussing the hopes and challenges of life between scans.
Highlighting Uruguay's advancements in dementia policy in August 2026: from ADI's high-level meeting with the Minister of Public Health, to joining the Economic Commission for Latin America and the Caribbean's Regional Conference on Population and Development.
Updates on recent blood tests including Elecsys® pTau217, developed by Roche in collaboration with Eli Lilly, as well as the Lumipulse G pTau 217 Plasma assay by Fujirebio Europe N.V.
July has seen increasing progression and activity towards the development of national dementia plans in the Americas region, from Colombia's first step towards a national dementia law to knowledge-sharing initiatives between Chile, Ecuador and Argentina, with regional collaboration playing an increasingly important role in advancing dementia policy across Latin America.
Access the world's first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.
Government representatives, dementia associations and WHO experts gathered in London to share progress, tackle challenges and strengthen collaboration on developing and implementing effective National Dementia Plans worldwide.
Highlights from the 79th World Health Assembly, a round-up of ADI's engagements at the annual gathering at WHO Headquarters, Geneva, Switzerland.
A commentary in response to the recent Cochrane review of clinical trial data on different anti-amyloid treatments, that states these medicines show ‘no clinically meaningful benefit’ for people with Alzheimer’s.